Enabling personalized cancer care

We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.

Learn more about Oncobit

Testimonial

Oncobit’s PM platform is transforming melanoma management, empowering clinicians to monitor disease progression and treatment response closely and reliably to improve clinical management.

Prof. Dr. med. Reinhard Dummer, Professor at University Zürich, Skin Cancer Expert, Senior Medical Advisor at Oncobit

With Oncobit PM integrated into our existing digital PCR workflow, we can closely monitor ctDNA changes and gain deeper insights into each patient’s melanoma. Its standardized software ensures consistency, crucial for routine clinical use.

Prof. Dr. med. Christoffer Gebhardt, Department of Dermatology and Venereology and University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Our Journey

January 2026

Launch of a Joint EADO–EUMelaReg ctDNA Project

We are pleased to announce the launch of a joint EADO–EUMelaReg project aimed at integrating circulating tumor DNA (ctDNA) into routine melanoma follow-up. The project will evaluate the clinical utility of ctDNA assessed using Oncobit’s CE-IVDR–marked digital PCR solution to detect relapse and to complement or potentially replace established monitoring approaches. By closely reflecting real-world clinical practice and leveraging the strengths of the EUMelaReg registry, this initiative seeks to advance precision monitoring in melanoma care.

Oncobit Partners with ID Solutions to Advance Precision Oncology

Oncobit is thrilled to announce a strategic partnership with ID Solutions, a leader in digital PCR–based oncology diagnostics. By combining ID Solutions’ highly sensitive biomarker detection technology with Oncobit’s monitoring assays and analytical software, this collaboration aims to accelerate cancer diagnosis and enable more precise, real-time treatment monitoring. Together, we are setting new standards for fast, reliable, and patient-centric oncology care in compliance with IVDR requirements.

Partnership with TrilliumBiO to advance US market entry

Oncobit is proud to partner with TrilliumBiO, a biomarker discovery company specializing in the development and commercialization of novel diagnostic tests. This partnership will not only broaden access to Oncobit's uveal melanoma solution for U.S patients but also improve patient management by integrating diagnostic insights with emerging therapies.